Canopy Biosciences
St Louis
About Canopy Biosciences
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $4.4M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2019)
- Website: canopybiosciences.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/canopy-biosciences-55214 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.